mafosfamide has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 10 (71.43) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dreger, P; Fruehauf, S; Ho, AD; Jens Zeller, W; Luft, T; Radujkovic, A; Topaly, J | 1 |
| Andersson, BS; Champlin, RE; de Lima, M; Decker, WK; Eaves, AC; Eaves, C; Jones, R; Lee, MS; Li, S; McMannis, JD; Ng, J; Niu, T; Robinson, SN; Shpall, EJ; Xing, D; Yang, H; Yao, X | 1 |
| Almici, C; Carlo-Stella, C; Dotti, GP; Garau, D; Mangoni, L; Piovani, G; Rizzoli, V | 1 |
| Bouchet, S; Capizzi, RL; Conlon, J; Douay, L; Giarratana, MC; Gorin, NC; Hu, C | 1 |
| Almici, C; Caramatti, C; Carlo-Stella, C; Cottafavi, L; Dotti, GP; Mangoni, L; Rizzoli, V | 1 |
| Almici, C; Caramatti, C; Carlo-Stella, C; Garau, D; Mangoni, L; Piovani, G; Rizzoli, V | 1 |
| Almici, C; Caramatti, C; Carlo-Stella, C; Dotti, GP; Mangoni, L; Rizzoli, V | 1 |
| Barletta, C; Calabretta, B; Chen, ST; Lange, B; Malaguarnera, L; Nieborowska-Skorska, M; Skorski, T; Szcyzlik, C | 1 |
| Calabretta, B; Christensen, L; Hoser, G; Iozzo, RV; Kawiak, J; Majewski, M; Nieborowska-Skorska, M; Perrotti, D; Skorski, T; Wlodarski, P | 1 |
| Agarwal, DP; Dereskewitz, C; Hassan, HT; Krueger, W; Meier-Tackmann, D; Zander, AR | 1 |
| Mangoni, L; Rizzoli, V | 1 |
| Becher, R; Becker, G; Schmidt, CG | 1 |
| Douay, L; Fouillard, L; Gorin, NC; Isnard, F; Laporte, JP; Lopez, M; Najman, A; Perot, C; Taillemite, JL; Van Den Akker, J | 1 |
| Ernst, P; Mortensen, BT; Philip, P | 1 |
1 trial(s) available for mafosfamide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Autologous transplantation for chronic myelogenous leukemia with mafosfamide-treated marrow.
Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Cyclophosphamide; Female; Follow-Up Studies; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Transplantation, Autologous | 1993 |
13 other study(ies) available for mafosfamide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Busulfan; Cell Proliferation; Cyclophosphamide; Drug Interactions; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Transplantation Conditioning; Tumor Cells, Cultured | 2014 |
A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Agents; Benzamides; Bone Marrow Purging; Cell Separation; Cell Survival; Cyclophosphamide; Flow Cytometry; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Cells, Circulating; Piperazines; Pyrimidines; Stem Cell Transplantation; Transplantation, Autologous | 2006 |
Selection of Philadelphia-negative progenitors from chronic myelogenous leukemia.
Topics: Antigens, CD; Antigens, CD34; Cell Adhesion; Cell Separation; Cyclophosphamide; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome | 1994 |
Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Topics: Amifostine; Antineoplastic Agents; Bone Marrow; Bone Marrow Purging; Bone Marrow Transplantation; Cell Death; Cyclophosphamide; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Autologous | 1995 |
Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide.
Topics: Adult; Bone Marrow; Bone Marrow Purging; Bone Marrow Transplantation; Chronic Disease; Cyclophosphamide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Survival Rate; Transplantation, Autologous | 1994 |
Fractionation of chronic myelogenous leukemia marrow cells by stroma adherence: implications for marrow purging.
Topics: Bone Marrow Cells; Bone Marrow Purging; Bone Marrow Transplantation; Cell Adhesion; Cell Separation; Cells, Cultured; Colony-Forming Units Assay; Cyclophosphamide; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1993 |
Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression; Hematopoiesis; Hematopoietic Stem Cells; Humans; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Oligonucleotides, Antisense; RNA, Messenger; Transplantation, Heterologous | 1993 |
Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Marrow; Bone Marrow Cells; Cyclophosphamide; DNA Probes; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Oligonucleotides, Antisense; Philadelphia Chromosome; Polymerase Chain Reaction; Survival Analysis; Thionucleotides; Treatment Outcome; Tumor Cells, Cultured | 1997 |
Changes in aldehyde dehydrogenase isozymes expression in long-term cultures of human hematopoietic progenitor cells.
Topics: Aldehyde Dehydrogenase; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Survival; Cells, Cultured; Cyclophosphamide; Gene Expression Regulation, Enzymologic; Hematopoietic Stem Cells; Humans; Isoenzymes; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Time Factors; Tumor Cells, Cultured | 1997 |
Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. The Italian Study Group.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Cyclophosphamide; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1990 |
Mafosfamide induces less sister chromatid exchange in Ph-positive cells than in normal bone marrow.
Topics: Bone Marrow; Cells, Cultured; Cyclophosphamide; Dose-Response Relationship, Drug; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Sister Chromatid Exchange; Tumor Cells, Cultured | 1990 |
[Bone marrow autograft treated with mafosfamide in the acceleration phase in chronic myeloid leukemia. Inversion of the clinical development].
Topics: Adult; Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Chronic Disease; Cyclophosphamide; Humans; In Vitro Techniques; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Transplantation, Autologous | 1989 |
Mafosfamide (ASTA-Z-7654) in vitro treatment of bone marrow does not eradicate Philadelphia-positive cells in chronic myeloid leukaemia.
Topics: Adult; Aged; Bone Marrow; Cell Division; Cell Transformation, Neoplastic; Cyclophosphamide; Female; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged | 1988 |